Zero Gravity Solutions, Inc.

Zero Gravity Solutions, Inc., an agricultural biotechnology company, focuses on the commercialization of technology derived from and designed for long term spaceflight and planetary colonization with applications to agriculture on earth. The company offers BAM-FX, an ionic nutrient delivery platform for food crops that deliver minerals and micronutrients systemically at the cellular level of a plant; and Directed Selection, which relates to the production and alteration of various novel stem cells with characteristics in the prolonged zero/micro gravity environment of the International Space Station. It patents its stem cells for commercial sale to third parties. The company was formerly known as ElectroHealing Technologies, Inc. and changed its name to Zero Gravity Solutions, Inc. in January 2013. Zero Gravity Solutions, Inc. was founded in 1983 and is headquartered in Boca Raton, Florida.

Zero Gravity Solutions, Inc. trades as ZGSI on OTC. The company is classified in Basic Materials / Agricultural Inputs and reports in USD.

The current profile places the business in Agricultural Inputs. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $45,263 of revenue and -$6.18M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Zero Gravity Solutions, Inc. can be compared against peers such as Angus Gold Inc., Bluestone Resources Inc., Allied Copper Corp., Eden Research plc, Harvest Minerals Limited, Kenongwo Group US, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $35.82M, beta of 1.05, and return on equity of +121.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ZGSI currently shows total debt of $4.48M and beta of 1.05. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: C-U (2024-07-05 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.zerogsi.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.